From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?

From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?

Whether smokers respond to anti-cancer drugs differently than non-smokers remains controversial. The objective of this study is to explore whether the better response of the smokers is specific to therapy of anti-PD-1/PD-L1, anti-checkpoint inhibitor, individual drugs on the cell surface, or lung ca...

Full description

Bibliographic Details
Main Authors: Lishi Wang, Fengxia Liu, Jing Li, Li Ma, Helin Feng, Qingyi Liu, William C. Cho, Haiyong Chen, Hong Chen, Hua Guo, Zhujun Li, Scott C. Howard, Minghui Li, Baoen Shan, Weikuan Gu, Jiafu Ji
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Journal of Personalized Medicine
Subjects:
cancer
clinical predictor
drug
hazard ratio
lung
smoking
Online Access:https://www.mdpi.com/2075-4426/11/9/914

Similar Items

Similar Items